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Abstract
Background: Glutaminase is expressed in most mammalian tissues and cancer cells, but the regulation of its expression is
poorly understood. An essential step to accomplish this goal is the characterization of its species- and cell-specific
isoenzyme pattern of expression. Our aim was to identify and characterize transcript variants of the mammalian glutaminase
Gls2 gene.
Methodology/Principal Findings: We demonstrate for the first time simultaneous expression of two transcript variants from
the Gls2 gene in human, rat and mouse. A combination of RT-PCR, primer-extension analysis, bioinformatics, real-time PCR,
in vitro transcription and translation and immunoblot analysis was applied to investigate GLS2 transcripts in mammalian
tissues. Short (LGA) and long (GAB) transcript forms were isolated in brain and liver tissue of human, rat and mouse. The
short LGA transcript arises by a combination of two mechanisms of transcriptional modulation: alternative transcription
initiation and alternative promoter. The LGA variant contains both the transcription start site (TSS) and the alternative
promoter in the first intron of the Gls2 gene. The full human LGA transcript has two in-frame ATGs in the first exon, which
are missing in orthologous rat and mouse transcripts. In vitro transcription and translation of human LGA yielded two
polypeptides of the predicted size, but only the canonical full-length protein displayed catalytic activity. Relative abundance
of GAB and LGA transcripts showed marked variations depending on species and tissues analyzed.
Conclusions/Significance: This is the first report demonstrating expression of alternative transcripts of the mammalian Gls2
gene. Transcriptional mechanisms giving rise to GLS2 variants and isolation of novel GLS2 transcripts in human, rat and
mouse are presented. Results were also confirmed at the protein level, where catalytic activity was demonstrated for the
human LGA protein. Relative abundance of GAB and LGA transcripts was species- and tissue-specific providing evidence of a
differential regulation of GLS2 transcripts in mammals.
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Introduction
The biological diversity of proteins in higher eukaryotes can be
increased by different processes operating at the transcriptional
level, where alternative splicing, alternative transcriptional initia-
tion, alternative polyadenylation, alternative promoters and RNA
editing represent the major mechanisms allowing the generation of
surprisingly great proteome diversity in higher eukaryotes despite
the relatively small gene number. Alternative transcription
initiation sites and alternative splicing are two well characterized
mechanisms providing transcript diversity [1,2]. Increasing
evidences support that most human genes present transcript
variants arising by one or combination of several transcriptional
regulation mechanisms. Thus, large-scale characterization of
human transcriptome indicates that between 69–75% of genes
undergo alternative splicing [3,4], 81% are subject to alternative
transcription initiation [5], 60% to alternative polyadenylation [6],
and 52% were subject to regulation by putative alternative
promoters [7]. Furthermore, investigations in recent years have
demonstrated the importance of transcript variant expression to
explain developmental changes, cell-specific differentiation pro-
cesses and metabolic deregulations conducive to pathological
states [8,9].
Glutaminase (GA
1; E.C. 3.5.1.2) plays essential roles in cell
bioenergetics and nitrogen metabolism by converting glutamine
into glutamate plus ammonium ions. Two different genes in
distinct chromosomes code for mammalian GA enzymes: the Gls
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gene encodes liver-type (L-type) isozymes [10]. Two K-type
transcripts have been described: the canonical KGA transcript
originally found in kidney and composed by 18 exons [11], and the
alternative spliced form named GAC, first described in human
kidney and colon cancer cells, which contains only 15 exons
[11,12]. On the other hand, nothing is known about the
expression and processing of L-type transcripts arising from the
Gls2 mammalian gene. The first L-type GA transcript, named
LGA, was cloned from rat liver and originally thought to be
present only in adult liver tissue [13,14]. Nevertheless, a second L-
type GA mRNA cloned from ZR-75 human breast cancer cells
[15], and later termed GAB [16], was demonstrated to be also
expressed in extrahepatic tissues, like brain, pancreas, human
cancer cells and cells of the immune system [15,17,18,19].
Glutaminases have attracted considerable attention in last years
because of the discovery of novel interacting partners and
subcellular locations which strongly suggest they behave as
multifunctional proteins, besides their roles as classical metabolic
enzymes. In tumor biology, a correlation between GA expression
and cancer growth and proliferation was early established,
supported by an enhanced mitochondrial glutamine catabolism
frequently exhibited by many types of tumor cells [20,21,22].
Recently, GA have fuelled attention in cancer research because of
key discoveries revealing their involvement as targets of oncogenes
and tumor suppressor genes. Thus, expression of human GLS gene
has been associated to oncogene c-Myc through a miRNA
mechanism allowing overexpression of K-type GA proteins in
parallel with cancer cell proliferation [23]. On the other hand,
GLS2 was demonstrated to be target of the p53 tumor suppressor
gene as mediator of p539s role in energy metabolism and
antioxidant defense [24,25]. A differential function of GA proteins
was first suggested by our group after examination of their pattern
of expression in several cancer cell lines and human tumors: GLS
isoforms were associated to tumorigenesis while GLS2 were
ascribed to cell differentiation [18]. It is presently unknown how
GA isoenzymes may undergo such different roles in tumor biology
[26].
Furthermore, some mammalian tissues and tumor cells show co-
expression of GLS and GLS2 isoforms [10,18], although the
physiological meaning of the existence of different GA transcripts
is not understood [17]. For example, we described a simultaneous
and differential expression of GLS and GLS2 proteins in
mammalian brain [27], in sharp contrast to the classical view
which postulated that KGA was the unique isoform expressed in
brain. The discovery of new tissues and cells expressing GLS2
proteins, along with novel characteristics and functions recently
suggested for GLS2 isoforms [28,29], call for a characterization of
different transcripts encoded by the mammalian Gls2 gene, as a
prerequisite to understand tissue-specific regulation of GA and
glutamine metabolism.
In this study, we use a combination of biochemical, molecular
biological, and bioinformatics approaches to show for the first time
direct evidence of the existence of alternative mRNA forms of the
orthologous Gls2 gene in mouse, rat and human. We conclude that
there are, at least, two sense transcripts encoded by the Gls2 gene:
a long canonical transcript containing all 18 exons of the CDS,
termed GAB, and a short transcript variant, LGA, which appears
by alternative transcription initiation. LGA variant uses an
alternative promoter located more than 7 kb apart from the
canonical GAB promoter, and has a distinct alternative first exon.
Interestingly, GAB and LGA are differentially expressed in
mammalian tissues and human cancer cells.
Materials and Methods
Ethics Statement
Rats were maintained in the Central Animal Housing Facility of
the University of Malaga at the Faculty of Medicine. The
maintenance of the animals as well as the experimental procedures
were in accordance with the European animal research laws
(European Communities Council Directives 86/609/EU, 98/81/
CEE, 2003/65/EC and Commission Recommendation 2007/
526/EC). Furthermore, all experimental protocols dealing with
animals here reported were previously approved by the Animal
Care Panel of the Center for Animal Experimentation of the
University of Ma ´laga.
Materials
Brain and liver poly(A)
+ mRNA from human and mouse were
purchased from Clontech. Male Wistar rats (9–10 weeks old) were
killed by decapitation and their tissues quickly removed and frozen
in liquid nitrogen. Rat liver and brain total RNA were isolated
using the RNeasy Mini KitH (Qiagen); DNase digestion was
completed during RNA purification using the RNase Free Dnase
Set (Qiagen), according to the manufacturer’s instructions. Total
RNA integrity was checked by agarose gel electrophoresis and
quantified using the 260 nm absorbance reading. RNA purity was
established by calculating the ratio of the absorbance readings at
260 and 280 nm.
Reverse Transcription (RT)-PCR Analysis
A universal RT primer previously used for cloning human
GAB, 59-CCGTGGGTCTAACTTCCGAGCAC-39, was em-
ployed for reverse-transcription of RNA isolated from the three
species tested (mouse, rat and human). Reverse transcriptase-
polymerase chain reaction (RT-PCR) was carried out using 1 mg
of total RNA or 0.5 mg of poly(A)
+ mRNA. RNA was converted to
first-strand cDNA using primer RT (2 mM) with SuperScript II
reverse transcriptase (GIBCO/BRL) and dNTP’s (10 mM each)
following standard procedures. For isolation of the full LGA
transcript from human poly(A
+)mRNA, retrotranscription was
done using a oligo(dT) primer at 10 mM concentration. The
cDNA was then treated with 2 units of RNaseH for 20 min at
37uC. For PCR amplification, 2 ml of cDNA reaction mixture
were combined with Advantage cDNA polymerase (Clontech) and
the respective primers at 500 nM. The sense (forward) primers
employed were: Intron1human, 59-ATCAGATGGCTTAAG-
GAGGAGGC-39, for partial amplification of the short L-type
(LGA) transcript from human liver and brain; Exon1rat, 59-
ATGCGCTCCATGAAGGCTCTG-39, for amplification of the
long L-type (GAB) transcript from human liver and brain, rat liver
and mouse liver and; Intron1mouse, 59-GCCAGATGGTT-
CAAAGAGGAGG-39, for amplification of the short L-type
(LGA) transcript from rat brain and mouse liver and brain. In
all cases, the antisense (reverse) primer was GSP-6, a universal
oligonucleotide deduced from the human GAB isoform: 59-
GCAGTGGTGAACTTGTGGATAGGG-39. Reactions were
carried out in a DNA Thermocycler iCycler (Bio-Rad) with the
following parameters: 1 cycle at 94uC for 5 min; 30 cycles at 94uC
for 1 min, 57uC–61,5uC (depending on the forward primer used)
for 45 s, 72uC for 2 min, and a final elongation step at 72uC for
7 min. For isolation of the full LGA transcript from human brain,
the primers employed were: hLGAfw: 59-GAGGACACTCACC-
TACTTATAAGCCC-39 and hLGArev: 59-
CTTCTCTGTACTCTGTCTGCTGAGG-39, and the PCR
programme was as follows: 1 cycle at 94uC for 1 min; 35 cycles
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extension at 68uC for 3 min.
Primer Extension Analysis
The hLGA cDNA clone obtained by RT-PCR was exploited to
design primers to determine the transcription start site. Three
primers were deduced from the first 400 nt of the hLGA cDNA:
anti-sense primers GSP-6, PEXT1 (59-CAGAGAATGGGGAG-
GAAAGTG-39) and PEXT2 (59-CATGGGCTTATAAG-
TAGGTGAGTG-39). The oligonucleotides were
32P end-labelled
with [c-
32P]ATP and T4 polynucleotide kinase. Poly(A)
+ mRNA
of human brain (approx. 0.5–1 mg) was mixed with the radioactive
oligonucleotides and reverse transcribed with avian myeloblastosis
virus reverse transcriptase, with the use of the protocol provided by
the manufacturer (Primer Extension Analysis kit; Promega). A
kanamycin-positive control RNA was run in parallel and the
primer extension products were analyzed on denaturing poly-
acrylamide analytical gels containing 8% (w/v) polyacrylamide,
7M urea and 1xTBE (Tris-borate-EDTA) buffer. Negative
controls with mRNA omitted were always run in parallel. Gels
were dried in a gel dryer at vacuum and revealed by
autoradiography. The size of the single-stranded cDNA products
(in bases) was estimated approximately by comparison with
FX174 HinfI DNA markers, using Image Lab software and a
Pharos FX Molecular Imager (Bio-Rad).
Western Assays and Analytical Determinations
Mitochondria from mouse liver and brain were isolated as
previously described [30]. Mitochondrial fractions were analyzed
by SDS-PAGE and Western blotting essentially as described [29].
Isozyme-specific antibodies against human L-type GA (GA-
B+LGA) and KGA were used as described before [27,30]. A
new polyclonal monospecific antibody was generated against the
human GAB isoform. This GAB-specific antibody was raised
against the synthetic peptide: RETPHSHQPQHQDH belonging
to exon 1 of human GAB and, therefore, not contained in the
LGA amino acid sequence. Antibodies were commercially
generated in rabbit after being crosslinked to keyhole limpet
hemocyanin (Genosphere Biotechnologies, France). The blots
were developed with the enhanced chemiluminiscence technique
as recommended by the supplier (Amersham Biosciences). Protein
content was determined by the Bradford method [31]. GA activity
was measured as described elsewhere [29] with minor modifica-
tions, by measuring the ammonium released in the GA reaction
with the OPA reagent. After in vitro transcription and translation,
the reticulocyte lysate was diluted into a small volume of GA
activity buffer (150 mM potassium phosphate, 1mM ammonim
chloride, pH 8.0). Then, the soluble extract was concentrated to
25 ml by ultrafiltration at 11,0006g using Centricon YM-30 tubes
(Millipore), and submitted to GA activity assay. The pGEM-
T[hLGA] construct cloned in the reverse (antisense) orientation
was always included as a control for zero background activity.
After GA reaction and before spectrophotometric determinations,
extracts were treated with 20% TCA to reduce background
absorbance due to hemoglobin and some other components of the
reticulocyte lysates.
Expression Analyses by Real-time RT-PCR
Total RNA (1 mg) or poly(A)
+ mRNA (500 ng) were reverse
transcribed using the Quantitec Reverse Transcription kit
(Qiagen) in a 20 ml reaction, according to the manufacturer’s
instructions. RNA samples were tested for genomic DNA
contamination by including no enzyme reverse transcription
(RT) controls, and for reagent and aerosol contamination by
including two no template controls. Real time PCR was carried
out with the CFX thermocycler (Bio-Rad). The rat 60 s ribosomal
protein L19 (Rpl19) and the mouse b-actin were used to normalize
experimental variability. The partial Rpl19, b-actin, KGA, GAB
and LGA transcript sequences were amplified using isoform-
specific primers (Table S1). Reaction efficiency was established for
each set of primers after quantification of eight different dilutions
of the DNA pool. Reactions were set up in a total volume of 25 ml
using 25 or 50 ng of cDNA, 2x Perfecta SYBR-Green Supermix
(Quanta Biosciences) and 200 nM of each transcript-specific
primer. The cycling conditions were: 95uC for 4 min, 40 cycles
of 95uC for 15 s, 61uC (mouse) or 63uC (rat) for 45 s and 72uC for
30 s. Fluorescence acquisition was carried out at 72uC. Specificity
of the PCR products was confirmed by analysis of the dissociation
curve. Each run included the RT-negative and non-template
control. Results were evaluated using CFX Bio-Rad Analysis
Software. Amplicon size and the absence of non-specific products
were confirmed by agarose gel electrophoresis. For absolute
quantification of both constitutive and GA transcripts, PCR
transcript-specific amplicons were prepared as a standard. PCR
products were analysed by 2% agarose gel electrophoresis and
purified (Illustra
TM GFX
TMPCR DNA and Gel Band Purification
Kit, GE Healthcare). Concentrations of purified nucleic acids were
determined by UV absorbance spectrophotometry. Tenfold serial
dilutions of the quantified amplicon solutions were kept in aliquots
at 220uC and used throughout the study as external standards of




The standard curve was created by plotting the threshold cycle
(Ct) corresponding to each standard, vs the value of their
corresponding log of starting quantity (pg). Ct is the number of
required cycles to reach the defined threshold level. Results in liver
and brain of the different GA transcripts were expressed as
numbers of molecules (6SEM) of mRNA per ng of total RNA or
mRNA, corrected for Rpl19 or b-actin constitutive values.
Absolute transcript copy number was calculated by using the
Avogadro constant (6.023610
23) and its molecular mass [32].
In vitro Transcription and Translation
The RT-PCR product of 1900-bp of human LGA cDNA was
cloned into the pGEM-T vector. This insert encompasses the
complete coding sequence, beginning 3 bp upstream of the start
codon and including 26 bp of 39-untranslated region. Human
LGA transcript variants lacking exon 4 and exon 10 were cloned
into pGEM-T and included as controls, as well as hLGA cloned in
the antisense orientation. We also prepared a deletion mutant
construct of human LGA starting at the second ATG codon of the
full transcript. Purified plasmids were transcribed and translated
using the TNT
TM-coupled reticulocyte–lysate system according to
the manufacturer’s instructions (Promega), using 1 mg of recom-
binant DNA and 20 mCi of [
35S]-Met in a total volume of 50 ml.
After 60-min incubation at 30 uC, aliquots were removed for
further experiments. Unlabeled methionine was added to the
extract used for GA activity assay. Expression reactions carried out
in parallel with 1 mg of the pGEM-T empty vector were used as
blanks. De novo synthesis of polypeptides was monitored by SDS/
PAGE and autoradiography. The films were analyzed with a
GS800 scanner employing Quantity One software (Bio-Rad).
Results
Isolation of Alternative Transcripts of Gls2 Gene
The first indication of the existence of transcript variants for the
mammalian Gls2 gene (Fig. 1) came about from sequence analysis
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Sequencing Consortium, GenBank and Ensembl databases of rat
and mouse. We notice that nucleotides at the 59-UTR and initial
coding sequence of rat liver LGA [33] matched with sequences
located at the 39-end of intron 1 of Gls2 in both human and mouse
genomic DNA, suggesting that a short LGA transcript might also
be expressed in these species. Therefore, RT-PCR experiments
were planned in human and mouse tissues to isolate short LGA
transcripts orthologous of the rat liver LGA [13].
For isolation of LGA transcripts by RT-PCR, sense oligonu-
cleotides were designed with sequences corresponding to the 39-
end of intron 1 of human [34] and mouse (NCBI Mus musculus
Genome Build 37.2) Gls2 genes. The human intron 1 primer was
used for amplification of the human LGA transcript in brain and
liver, whereas the mouse intron 1 primer was used indistinctly for
mouse and rat LGA amplifications. In all cases, the antisense
primer GSP-6, which anneals to exon 2 of human GLS2 gene and
to exon 1 of mouse and rat genes, was employed. PCR products of
the expected lengths and with highly similar sequences to that of
rat liver LGA (Fig. 2, top panel) were obtained, thus getting proof
of the expression of LGA transcript forms in tissues and species
distinct from rat liver. Furthermore, BLAST analysis of exon 1 of
human GAB mRNA [10,34] against rat (Rnor 3.3, Rat Genome
Sequencing Consortium) and mouse (Ensembl v35) genomic
sequences identified a homologous region (.95% identity) in the
59-flanking region of both Gls2 genes, about 5.2 kb and 4 kb
upstream of their respective transcription start sites (TSS) in rat
chromosome 7 and mouse chromosome 10. Therefore, a RT-PCR
strategy was designed to proof the existence of orthologous GAB
transcripts in liver and brain from rat and mouse. The isolated
RT-PCR products (Fig. 2, bottom panel) display great homology
with the human GAB cDNA cloned from ZR-75 breast cancer
cells [15], proving that GAB transcripts are indeed expressed by
rat and mouse.
Once we showed co-expression of GLS2 transcripts in
mammalian tissues, thereby demonstrating that human GAB is
not the orthologous transcript of rat liver LGA, we cloned the full
length LGA transcript from human brain for further character-
ization and functional studies. The transcript was fully sequenced
(GenBank# 775422, Fig. 3) and its sequence compared with rat
liver LGA cDNA. Overall, human LGA nucleotide sequence
shows an 89% identity with rat liver LGA (BLAST analysis); it has
a 1698 nt ORF encoding a putative protein of 565 amino acids
(Fig. 3). The deduced amino acid sequence was also highly similar,
with a 91% of identity with regard to both rat LGA and human
GAB proteins (Clustalw analysis) (Figure S1).
Three further non-coding GLS2 transcripts, containing prema-
ture stop codons, were isolated during cloning studies of LGA
(results not shown). Two of them were non-sense human brain
transcripts lacking exons 4 and 10, respectively (GenBank#
Figure 1. Structure of the human GLS2 gene and predicted GA transcripts. The GLS2 gene is located in the 12q13 region of human
chromosome 12, as shown in the upper part of this figure. The gene has a length of approximately 18 kb and split into 18 exons. Exon sequences are
indicated as numbered light green boxes; intron sequences are shown as solid blue lines. Two GA transcripts are encoded by GLS2: the canonical GAB
mRNA formed by joining the full 18 exons of the gene and the short LGA transcript that lacks exon 1. Dotted lines comprise exons involved in the
generation of both transcript variants. The transcription start site is marked by an arrow and numbered as +1.
doi:10.1371/journal.pone.0038380.g001
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reading frame giving rise to premature stop codons. The third
non-sense transcript was cloned from mouse brain by RT-PCR; in
this case, a partially-retained intron 2 was present in the sequence
giving rise to a non-sense transcript (GenBank# EU770627).
Finally, we also identified expressed-sequence tags (EST’s)
supporting Gls2 GAB transcripts. The human GAB genomic
sequence [34] was screened against the human EST database. The
same analysis was made with the rat and mouse Gls2 gene
sequences deposited in the current version of the NCBI rat
Figure 2. Comparison of the sequences of RT-PCR products demonstrating co-expression of LGA and GAB transcripts in mouse, rat
and human tissues. The identity of each amplified fragment was assessed by sequence alignment with known sequences for rat liver LGA
(GenBank# J05499) and human GAB (GenBank #AF348119) using Blast program. Top panel: the 59-sequences of mouse brain and human liver LGA
cDNA fragments obtained by RT-PCR were aligned with the sequence of rat liver LGA cDNA; bottom panel: the 59-sequences of rat liver and mouse
brain GAB cDNA fragments obtained by RT-PCR were aligned with the human GAB sequence from ZR-75 breast cancer cells. Identical nucleotides are
indicated in red, different nucleotides are labeled in blue. Sequence alignment was done using Multalin program (http://multalin.toulouse.inra.fr/
multalin/).
doi:10.1371/journal.pone.0038380.g002
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EST supported the existence of GAB long transcripts in each
species: GenBank #BC104712 and #BC089776 in rat; GenBank
#AI195692.1, #BB633707.1 and #BY243446.1 in mouse. In
contrast, we did not find any EST for LGA transcripts in human,
mouse and rat EST databases. The absence of EST LGA-specific
may be due to the fact they must reach the distinct 59-UTR
sequence of LGA, a GC-rich region hard to transcript.
Transcript Variant LGA Appears by Alternative
Transcription Initiation and has Alternative Promoter
Sequence analysis of GAB and LGA variants clearly supports
that LGA short transcript appears by alternative transcription
initiation, because its TSS was located at the 39-end of the first
intron of the Gls2 gene. Taking into account the length of this
intron (more than 7 kb in human, .4 kb in rat and mouse), an
alternative promoter, different from the one used by GAB, must
necessarily exist in this 59-flanking region. To map this regulatory
region, we performed primer extension analysis to exactly localize
the TSS of human LGA (Fig. 4). Although three different primers
were employed, only one of them was able to prime consistently
the reverse transcriptase enzyme, giving rise to two bands in the
autoradiography (Fig. 4). The upper band has an apparent
molecular mass of 140 nts by comparison with standard molecular
markers ran parallel in the same gel. This means that human LGA
transcription starts at the adenine nucleotide located 140 nts
upstream of the translation start codon (Fig. 3). The sequence of
the TSS conforms to consensus sequences for eukaryotic
transcription starts and is almost identical to the transcription
initiation site of the orthologous rat liver LGA mRNA [33].
Obviously, the most plausible candidate for alternative
promoter of the human LGA transcript is the sequence upstream
of its TSS at the 39-end of intron 1. Bioinformatics analysis of the
approximately 1,5-kb sequence 59 distal to the transcription
initiation supported this functional role: many transcription factor
recognition sites are present in this region (Fig. 5), strongly
suggesting that this is a functional promoter for LGA. Main
transcription boxes found were AP-1, TATA-like, GATA-1,
CAAT, SP1 and p53. Interestingly, a distal promoter region was
also predicted for the first kb of intron 1, almost 7 kb away from
the TSS, which contains c-Myb, c-Myc, AP-2, NF-kappa B and
some other consensus boxes (Fig. 5).
Converging evidence supporting the 39-end of intron 1 as an
alternate promoter which regulates LGA transcription was also
obtained from the Encyclopedia of DNA elements (ENCODE)
produced by the ENCODE Consortium (The ENCODE Project
Consortium 2007). Analysis of the human GLS2 genomic locus for
the presence of enhancer- and promoted-associated histone marks
(H3K4Me1 and H3K27Ac) in several human cell lines detected
three main regions: the GAB canonical promoter, the alternative
LGA promoter and a distal region located at the 59-end of intron 1
(Fig. 6). However, the H3K4Me3 track, a histone mark associated
with promoters, only detected the GAB promoter and the
enhancer region at the beginning of intron 1, both in human
cell lines and frontal cortex (Fig. 6). The presence of CpG islands
differs notably in both promoters: the GAB promoter has an
extremely high content while, in sharp contrast, no CpG islands
are present in the LGA promoter (Fig. 6). Finally, the methylation-
dependent immunoprecipitation of DNA and sequencing (MeDIP-
seq) data for GAB and LGA regulatory regions in human brain
Figure 3. Nucleotide and deduced amino acid sequences of human LGA transcript. The short LGA transcript variant was cloned by RT-PCR
from human brain mRNA as described in the Materials and Methods section. The cloned cDNA was fully sequenced: nucleotide and deduced amino
acid sequences are shown. The two initials ATG start codons are labeled in red; 59-UTR and 39-UTR regions are marked in yellow. Amino acid 1 is the
initiation methionine and the stop codon is indicated by the asterisk. Sequences were arranged using Prettyseq program (http://emboss.sourceforge.
net/apps/release/6.4/emboss/apps/prettyseq.html).
doi:10.1371/journal.pone.0038380.g003
Figure 4. Primer extension analysis of human brain RNA.
Oligonucleotides GSP-6, PEXT1 and PEXT2 flanking the 59 termini of the
human LGA cDNA clone were
32P end-labeled with [c-
32P]ATP and T4
polynucleotide kinase. Poly(A)
+ mRNA of human brain (approx. 0.5–
1 mg) was mixed with the radioactive oligonucleotides and reverse-
transcribed with avian myeloblastosis virus reverse transcriptase; the
products from primer extension reactions were separated by electro-
phoresis on an 8% (w/v) denaturing polyacrylamide gel. Lanes are
labeled with the name of the specific primer used in each case. The size
of the single-stranded cDNA products (in bases) was estimated
approximately by comparison with FX174 HinfI DNA markers shown
at the left in lane M. C+ lane: product amplified with a positive control
of kanamycin. C- lanes: negative controls using PEXT2 with mRNA
omitted. The black arrow indicates the specific GA products of approx.
140 bases obtained by reverse transcription with primer PEXT2. Top
panel: scheme showing the approximate position of the three primers
with regard to the TSS (+1) and the two first ATG codons of human LGA
transcript.
doi:10.1371/journal.pone.0038380.g004
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promoter regions for LGA do not show DNA methylation, while
the proximal GAB promoter appears methylated (Fig. 6).
Quantification of GAB and LGA Transcript Levels by Real-
time PCR
We devised a real-time PCR method for quantification of the
two L-type GA transcript variants in brain and liver tissues. The
relative abundance of both L-type transcripts was tissue-specific
and, more surprisingly, also species-specific. Thus, while LGA was
slightly more abundant than GAB in mouse brain, the opposite
was found in rat brain where GAB mRNA was fourfold the
amount of LGA (Fig. 7). As a reference and useful control of
the qPCR method developed, we also quantify the copy number
of the KGA mRNA transcript. In mouse brain, KGA abundance
was 15 times higher than the sum of L-type transcripts (GAB +
LGA), reinforcing the role of KGA as the major isoform in this
tissue (Fig. 7). The number of copies of KGA was
46.96610
469.48610
4, while that of L-type GA (GAB+LGA)
was only 3.02610
460.33610
4. Similar results were found in rat
brain, where KGA was again the most abundant isoform with a
copy number 21-fold higher than that of LGA+GAB transcripts
(Fig. 7).
In contrast, liver tissue lacks significant amount of KGA
transcript and, therefore, it became a good control for our qPCR
assay. The abundance of L-type transcripts in liver was absolutely
dependent on the species being analyzed. Thus, while GAB was
the predominant isoform in mouse liver, showing an 11-fold
higher abundance than LGA, short transcript LGA was five-times
more abundant than GAB in rat liver (Fig. 7). This strikingly
different expression pattern observed for GLS2 transcript variants
was unexpected and implies selective transcriptional regulatory
mechanisms being operative in distinct tissues and mammalian
species.
Expression of Gls2 Protein Isoforms: in vitro Transcription/
translation and Immunoblot Analysis
Human LGA transcript possesses two in-frame ATGs in the first
exon which are lacking in the orthologous transcripts from mouse
and rat (Figs. 2 and 3). Both ATGs are surrounded by a sequence
(CCCATGT and GGCATGC) at positions 83 and 218 of their
respective mRNAs (Fig. 3), which match reasonably well with the
Kozak consensus sequence for an optimal translation initiation in
eukaryotes [35]. Interestingly, the Kozak sequence for the second
ATG of human LGA is identical to that present in the long GAB
transcript variant [15]. The open-reading frames (ORFs) begin-
ning at the first two ATGs of human LGA encode putative
proteins of 556 and 526 amino acids, respectively, with theoretical
molecular masses of 56 and 51 kDa.
The proteins encoded by the cloned human LGA cDNA were
demonstrated using the TnTH T7 in vitro transcription/translation
system. We cloned the whole coding cDNA sequence of human
brain LGA into the pGEM-T vector. Using a reticulocyte lysate
system, the in vitro transcribed and translated [
35S-Met]-LGA
protein was analyzed by SDS-PAGE and autoradiography: two
major bands were clearly seen at molecular masses compatible
with proteins coded from alternative translation start ATGs
(Fig. 8). Human LGA transcript variants lacking exon 4 and exon
10 were included as controls, as well as hLGA cloned in the
antisense orientation: no relevant protein bands were detected
(Fig. 8). In order to assure that both bands in the autoradiography
correspond with proteins translated from the first two start codons,
and not with shorter polypeptide products from downstream ATG
codons, we prepared a deletion mutant construct of human LGA
starting in the second ATG codon of the full transcript.
Transcription and translation of this mutant cDNA yielded a
clear protein band fully coincident with the lower band of the
doublet seen for the LGA full transcript (Fig. 8). Thus, we
confirmed that proteins translated from the two first start codons
of the human LGA transcript can be obtained in roughly similar
yields by using an in vitro reticulocyte system.
Then, we tried to discriminate whether any of the LGA proteins
produced in vitro was catalytically active. To answer this issue, cold
aliquots of the in vitro translated proteins were evaluated for
enzymatic activity. The reticulocyte lysate was clarified by
ultrafiltration to remove potential contaminants that may interfere
with the assay; furthermore, the buffer composition and pH of the
translation mixture were also changed to reach optimum values for
L-type GA [29]. GA activity was consistently detected well above
Figure 5. Main transcription factor recognition sites presented in the alternative promoter of the human LGA transcript. Schematic
diagram showing the 7,341 kb of intron 1 of the human GLS2 gene. The transcription start site is indicated by +1. The sequences from nt -7340 to nt -
6540 (enhancer distal region) and from nt -1500 to nt +1 (proximal promoter) are represented. Main putative protein binding sites, determined by
computer analysis, are identified by vertical bars and are named in bold letters below the sequence. The program TESS (http://www.cbil.upenn.edu/
tess) was employed for searching consensus transcription factor motifs. A second p53 motif, found in between distal and proximal promoters, is
shown in normal type characters.
doi:10.1371/journal.pone.0038380.g005
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translated products from human LGA full transcript. The GA
activity account for 318.50613.84 mU/ml (nmoles of glutamate
produced per min and ml of extract), the mean value for three
different transcription/translation mixtures assayed (Fig. 9). How-
ever, the mutant LGA construct, starting at the second ATG
codon of the ORF, only yields a residual near background GA
activity (Fig. 9), even though it was satisfactorily translated (Fig. 8).
Finally, the existence of LGA and GAB transcript variants in
mammalian tissues was also assessed at the protein level by
immunoblot analysis. The presence of protein products encoded
by both alternative transcripts was revealed by using isozyme-
specific antibodies against human L-type GA [27], which are able
to recognize both GAB and LGA protein isoforms, and polyclonal
antibodies monospecific for GAB protein raised against a synthetic
peptide from exon 1, an amino acid sequence belonging
exclusively to the GAB isoform. Human neuroblastoma SHSY-
5Y cells express both GLS2 transcript variants (as checked by
qPCR analysis, results not shown) and were used as a control for
antibody validation in mammalian tissues. Two bands of the
expected molecular masses for GAB and LGA peptides were
revealed with the antibody recognizing common epitopes of both
isoforms in neuroblastoma cell extracts (Fig. 10, central panel).
Accordingly, the lower molecular mass band disappeared when a
similar blot was revealed with GAB-specific antibodies (Fig. 10, left
panel). Then, we assayed rat liver and brain mitochondria: a
doublet of protein bands, with molecular masses consistent with
GAB and LGA polypeptides, was seen in rat liver probed with
antibodies recognizing both isoforms (Fig. 10, right panel).
Interestingly, the lower LGA band displayed a stronger intensity
than GAB, in agreement with the qPCR results of rat liver (Fig. 7).
Finally, in rat brain mitochondria the lower LGA band was barely
detected and only the GAB protein was revealed (Fig. 10, right
panel), a result consistent with the relative transcript abundance
determined by qPCR in rat brain tissue (Fig. 7).
Discussion
Isoform-specific RT-PCR in brain and liver of three mamma-
lian species –human, rat and mouse- demonstrates co-expression
of two GLS2 transcript variants showing alternative first exons
(Figs. 1 and 2): a long GAB transcript, previously cloned from ZR-
75 breast cancer cells [15], and a short LGA transcript, lacking the
first exon of GAB, and first characterized in rat liver [13,33].
When we carried out these initial RT-PCR experiments, the Gls2
gene in the rat and mouse genome databases had 17 exons and
neither of them contained exon 1. The current version of genomic
sequences for Rattus norvegicus strain BN/SsNHsdMCW
(RGSC_v3.4) and Mus musculus (Ensembl mouse database,
NCBIm37 sequence assembly) include transcript variant GAB
based on similarity searches with human GAB, human GLS2 gene
Figure 6. ENCODE Enhancer- and Promoter-Associated Histone Marks, CpG islands and methylation status of the GLS2 gene locus
on human chromosome 12. For simplicity, only the four first exons of human GLS2 gene and the 59-flanking genomic region are shown on top of
the Figure. Below the GLS2 gene, six plots are represented, as follows: first panel: Enhancer- and Promoter-Associated Histone mark (H3K4Me1) from 9
human cell lines; second panel: Promoter-Associated Histone mark (H3K4Me3) from 8 human cell lines; third panel: Enhancer- and Promoter-
Associated Histone mark (H3K27Ac) from 8 human cell lines; fourth panel: CpG island shown as a solid green bar; fifth panel: Promoter-Associated
Histone mark (H3K4Me3) from chromatin immunoprecipitation of DNA and sequencing data (ChIP-seq) and; sixth panel: Methylation-dependent
immunoprecipitation of DNA and sequencing data from human brain (MeDIP-seq).
doi:10.1371/journal.pone.0038380.g006
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in this study clearly support that GAB and LGA transcripts are co-
expressed in liver and brain tissue from human, mouse and rat.
LGA protein isoforms display a very high degree of homology in
human, mouse and rat, showing more than 91% of identity in
their amino acid sequences. As paralogous genes, Gls and Gls2 are
presumed to have been derived by gene duplication followed by
gradual changes in the sequences of both copies. Analysis of the
coding sequences of human GA genes suggests that they have
evolved from a common ancestral gene [34], as was previously
noted for the rat genes [33]. Interestingly, paralogous proteins may
acquire different functions during their evolution while maintain-
ing a strong similarity in sequence and three-dimensional
structure. In contrast with the GLS isoforms KGA and GAC,
which mostly differ in their C-terminal regions, the only
differences in GLS2 isoforms appear at the N-terminal region.
Interestingly, the human LGA isoform is longer than its mouse
and rat counterparts, showing an extension of 30 amino acids at
the N-terminal end: 24 novel amino acids followed by the first 6
amino acids of exon 2 of human GAB (Fig. S1). The N-terminal
region of GA is related with subcellular location and posttrans-
lational processing [28]. Bioinformatics analysis of human LGA
protein does not find a consensus mitochondrial targeting
sequence at its N-terminus; however, a secretory signal peptide
was predicted for the first 16 amino acids of the LGA protein
translated from the second ATG [36].
Cloning of the human LGA transcript (Fig. 3) allowed the
discovery of the transcriptional mechanism regulating GLS2
transcript products. Primer extension analysis revealed the LGA
transcription start site, mapping to the 39 end of intron 1 of the
GLS2 gene (Fig. 4). This site showed great sequence identity with
the TSS of rat liver LGA. In addition, TATA-like and CAAT
boxes were present at consensus distances from this transcription
initiation site. The cloning and primer extension data for human
LGA unambiguously demonstrate that this isoform arises by
alternative TSS of the GLS2 gene.
Figure 7. Quantification of mRNA levels of KGA, GAB and LGA transcripts in rat and mouse tissues by qPCR. The histogram shows the
absolute copy number of mRNA transcripts for the KGA (dark blue), GAB (pink) and LGA (light blue) isoforms. Real time RT-PCR was performed as
indicated in the Materials and Methods section. Results are mean 6 S.E.M. of three independent experiments done in triplicate. Values were
determined for liver and brain tissues from rat and mouse and are shown as copy number per ng of total RNA. Insets: GAB and LGA mRNA values in
mouse and rat brains are depicted without KGA mRNA levels to appreciate differences among them.
doi:10.1371/journal.pone.0038380.g007
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intron 1 immediately suggests the presence of an alternative
promoter for this isoform, because the GAB canonical promoter is
more than 7 kb apart from the TSS of human LGA. As expected,
the last 1,5 kb of intron 1 has many transcription factor
recognitions boxes. Of note, three DNA binding consensus
sequence for p53 in the human GLS2 gene were recently found:
one in the canonical GAB promoter and two others in intron 1,
reinforcing the view that this is a true promoter for the LGA
transcript [24]. Moreover, bioinformatics analysis of intron 1
yields potential recognition binding sites for AP-1, GATA-1, C/
EBP and SP-1 in the near promoter region and also detects a distal
regulatory enhancer region almost 7-kb away from the TSS
(Fig. 5). Sequence analysis of alternative and canonical human
GLS2 promoters did not show significant homology between them.
The promoter of the orthologous rat LGA transcript was
previously cloned and sequenced (GenBank# L76175) [33].
Nowadays, it can be mapped at the end of intron 1 of the rat
Gls2 gene, approximately 1.1 kb upstream of exon 2 in the current
version of rat chromosome 7 (Rat Genome Database, v3.4, http://
rgd.mcw.edu/). Taken together, experimental and bioinformatics
data point toward the same conclusion: LGA arises by direct
transcription of the Gls2 gene from an alternate promoter located
at the end of intron 1.
Canonical and alternate GLS2 promoters differ in basic
elements like CpG islands (Fig. 6). This difference has been noted
previously as a kind of hallmark for alternative promoters, whose
frequency of CpG islands was less than half of that seen in normal
canonical promoters [7]. In addition, it has been shown that CpG-
containing promoters have a ubiquitous expression [37], whereas
almost a triple number of alternative promoters, on average, show
tissue-specific or signal-dependent expression instead of being
ubiquitously expressed [7]. Therefore, the distinct CpG content
paves the way for a differential regulation of both transcripts by
epigenetic mechanisms. Furthermore, the pattern of methylation
of both promoters is quite different (Fig. 6). The existence of
separate methylated and unmethylated promoters for the same
human gene has been recently highlighted as a mechanism for
regulation of alternative transcription in normal differentiation
and cancer, allowing expression of a gene even though its
canonical 59-promoter remains methylated [38,39]. Thus, DNA
methylation may control alternative promoter usage.
Although alternative promoter use was first described in 1981
[40], its relevance for generation of protein and regulatory
diversity has not been fully appreciated until quite recently. The
use of alternative promoters does not always result in the
production of different proteins; in fact, it appears that 60–80%
of genes with alternative promoters produce transcripts with
identical ORFs [41]. A recent study for alternative promoters of
human genes using exon-microarray data identified 7,708 genes
with alternative promoters, of which 57% transcribed a common
first exon and only 42% transcribed a distinct alternative first
exon; in all cases, the alternative promoter was fully embedded in
an intron [42]. In the case of GLS2, the alternative promoter is
fully embedded in intron 1, yields a transcript with a distinct first
exon and translates a protein isoform with different N-termini
(LGA). Thus, GLS2 has a novel intronic CpG-less promoter and,
therefore, must be added to the ongoing annotation and
expanding list of alternative promoters of human genes. It is
noteworthy that human genes with distinct alternative first exons
possess a 2-fold higher occurrence of promoters lacking CpG-
island in one of their TSSs [42], exactly as happens with GLS2.
Interestingly, previous work has found that brain is one of the
tissues where the presence of alternative promoters of human
genes was most abundant [7]. The same authors reported that
about 52% of the total human genes were subject to regulation by
putative alternative promoters, and genes encoding signal-trans-
Figure 8. In vitro transcription and translation of human LGA
cDNA. The ORF of human LGA (hLGA), deletion mutant hLGA (Mut-
hLGA) starting at the second ATG, and D4- and D10-LGA deletion
mutants were cloned into the pGEM-T vector and transcribed and
translated in vitro in the presence of
35S-Met. The reaction mixtures
were then analyzed by SDS-PAGE and autoradiography. Lane M,
standard protein markers with the relative positions of prestained
molecular mass markers indicated on the left; lane Mut-hLGA, aliquot of
the translation mixture using the human LGA cDNA starting at the
second in-frame ATG; lane hLGA, full-length human LGA; lane Mut-D4,
aliquot of the translation mixture using the D4-LGA deletion mutant
cDNA; lane Mut-D10, aliquot of the translation mixture using the D10-
LGA deletion mutant cDNA; lane C-, negative control (pGEM-T with the
hLGA cloned in the antisense orientation); lane C+, luciferase positive
control. The radioactive LGA protein bands are indicated on the left
using black arrows.
doi:10.1371/journal.pone.0038380.g008
Figure 9. Glutaminase activity assay. The in vitro transcribed and
translated human LGA (hLGA) protein and a deletion mutant (Mut
hLGA) protein, starting at the second ATG initiation codon, were
assayed for GA activity as described in the Materials and Methods
section. Results are mean 6 S.E.M. of three independent experiments:
protein hLGA (pink bar); protein Mut hLGA (blue bar). Background
activity was measured by using the pGEM-T[hLGA] construct cloned in
the antisense orientation and was always subtracted from activity
values obtained with the hLGA proteins. Values are expressed as
milliunits of enzyme activity per ml.
doi:10.1371/journal.pone.0038380.g009
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promoters. It is tempting to speculate that GLS2 transcripts may
have this kind of regulatory mechanism in brain because the
function of GAB and LGA transcripts might be associated to
signaling or regulatory functions, besides their role as glutamate-
producer enzymes [28,43].
Another posttranslational mechanism recently discovered is
nonsense- mediated mRNA decay (NMD). Large-scale analysis of
alternative isoforms of known human genes found that one-third of
the alternative transcripts examined contained premature termi-
nation codons [44]. The authors concluded that coupling of
alternative splicing and NMD is an important mechanism of
regulating protein expression. Interestingly, both GA human genes
were found to be targeted for NMD in this study: two NMD-
candidates were reported for GLS2 and one for GLS [44]. Here, we
have annotated two more non-coding RNAs for human GLS2
(lacking exons fourth and tenth, respectively) and one for mouse
Gls2 (partially retained intron), supporting the view that NMD
may play a functional role in regulating GA protein expression
levels.
The final aim of our study on transcriptional regulation of the
Gls2 gene will be a full description of the in vivo function of both
alternative products. Actually, alternative promoter may play a
role in generating species-specific diversity, as can be inferred from
our results on relative abundance of GAB and LGA in rat and
mouse tissues. An unexpected result was the dramatic change in
transcript levels observed in liver: GAB was the most abundant
isoform in mouse (11-fold vs LGA), but not in rat where LGA
predominates over GAB almost in the same proportion (10.5-fold).
In brain, the pattern of mRNA expression was the opposite of that
previously found in liver: LGA was the main isoform in mouse
while GAB showed the greatest abundance in rat. In rat and
mouse brain, KGA was clearly the predominant isoenzyme
accounting for more than 90% of total GA transcripts. As far as
we know, this is the first report quantifying the mRNA levels of
main GA isoforms (KGA, GAB and LGA) in whole brain of
mammals.
Alternative mRNA isoforms not always translate into different
protein isoforms and can be involved in regulation of translation
initiation, RNA editing and other processes. Therefore, we
searched for additional experimental evidences at the protein
level to assess the functionality of GLS2 mRNA variants. When
the cloned human LGA cDNA was in vitro transcribed and
translated two protein bands labeled with [
35S]-Met were clearly
seen. By running a parallel deletion mutant construct, with its
ORF starting at the second in-frame ATG of the LGA transcript,
we were able to conclude that both bands correspond to products
arising from the first two in-frame ATG of its sequence. When
activity assays were set using the in vitro translated products, GA
activity was consistently detected for the whole LGA cDNA
construct but not for the deletion mutant. This result agrees with
the fact that full-length LGA protein, starting at the first ATG, was
the only product displaying catalytic activity, even though protein
translation may start from any of the two initial ATGs with
roughly equal efficiency, at least in the rabbit reticulocyte lysate
system. Taken together, the results point toward the existence of
only one functional human LGA: the protein translated from the
first start codon of its mRNA sequence.
On the basis of differences in molecular structure, kinetic
behavior and subcellular location we first concluded that human
GAB should be a new GA isozyme and not the human
orthologous of the rat liver enzyme [16,29]. Now, we have found
conclusive experimental evidences supporting that hypothesis.
Western blot results in rat liver tissue were consistent with co-
expression of GAB and LGA proteins. Two main bands with
apparent molecular masses compatible with GAB and LGA
isoforms were detected with polyclonal antibodies against the
whole GAB protein (Fig. 10). A similar result was previously
obtained in mouse liver mitochondria [30]. To obtain further
insights into their identity, we probed the blots with an isoform-
Figure 10. Immunoblot analysis of human SHSY-5Y neuroblastoma cells and rat liver and brain mitochondria. Cell extracts of human
neuroblastoma SHSY-5Y cells (left and center panel) and mitochondria isolated from rat liver and brain (right panel) were analyzed by SDS-PAGE and
Western blotting. Blots were revealed by chemiluminescence using polyclonal antibodies raised against the exclusive first exon of human GAB
protein (left panel) or against the whole human GAB protein which recognize both GAB and LGA proteins (center and right panel). M, lanes
containing the molecular mass markers indicated on the left margin; SHSY-5Y, lanes loaded with protein extracts isolated from human neuroblastoma
cells; Liver 1 and 2: lanes containing total liver protein extracts and mitochondrial protein extracts, respectively; Brain 3 and 4: lanes containing total
brain protein extracts and mitochondrial protein extracts, respectively.
doi:10.1371/journal.pone.0038380.g010
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transcript: in this case, the lower molecular mass band disappears.
This result is in accordance with GAB being the protein with
higher molecular mass and LGA the lower band in the doublet
detected in rat liver. The two GLS2 peptides from the brain
appear to differ in size somewhat from the peptides in the liver,
probably reflecting a different pattern of posttranslational modi-
fications. Interestingly, a similar behavior was already detected in
mouse liver and brain mitochondria [30]. In summary, the protein
expression results support those obtained at the mRNA level and
suggest a parallel behavior between transcript abundance and
protein concentration for each GLS2 isoform.
Our finding of alternative L-type transcripts by use of alternate
promoters and consequent alternative use of first exons for the
mammalian Gls2 gene may explain most of the previous
experimental data suggesting the existence of two L-type isoforms.
Further studies will be needed to detail the in vivo function of the
alternative products of the mammalian Gls2 gene. Work is in
progress to fully characterize the transcriptional and posttran-
scriptional regulation of GAB and LGA transcripts and their
relevance in cancer and other diseases.
Supporting Information
Figure S1 Comparison of N-terminal amino acid se-
quences of LGA and GAB proteins from mouse, rat and
human tissues. Sequence alignment of the N-termini of the
indicated proteins were done using Multalin program (http://
multalin.toulouse.inra.fr/multalin/). For the sake of clarity, the
same order as in the nucleotide sequence comparison shown in
Fig. 2 was maintained. Top panel: amino acid sequences of mouse
brain and human liver LGA were aligned with the sequence of rat
liver LGA; bottom panel: amino acids of rat liver and mouse brain
GAB proteins were aligned with the N-terminal sequence of
human GAB from ZR-75 breast cancer cells. Identical amino
acids are indicated in red, different amino acids are labeled in
blue.
(TIF)
Table S1 Oligonucleotide sequences used for real-time
RT-PCR of GAB- and LGA-specific amplicons in brain
and liver tissues from rat and mouse. The nucleotide
sequences for sense (forward) and antisense (reverse) primers used
in the real-time RT-PCR experiments are shown. Mouse primers
are indicated with the abbreviation ‘‘m’’ and rat primers with ‘‘r’’.
Primers employed for the house keeping genes b-actin and Rpl19
are also shown. The size of the expected amplified products (in
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